profit from every $100 of sales.
$0$100
Certara
$11.57-2.77% today
+37.6% in 1 year
1-year low $4.481-year high $12.22
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Certara sold, what it kept, and what it did with the cash.
Sales went from $336 million in 2022 to $419 million in 2025, with -$1.60 million of profit last year.
SalesProfit
Certara handed back 61% of the cash it generated last year.
Buybacks $43M
Free cash flow 2025$70M
Bought back its own shares$43M
Paid as dividends–
Cash vs. debt$189M vs. $306M
Certara vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Certara | No profit yet | ||
 GE HealthCare Technologies | 18.0× · Fair price | ||
 BrightSpring Health Services | 74.3× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.8× · Expensive |
AI analysis
An AI analyst reads Certara's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 336 | 354 | 385 | 419 | |
| 203 | 213 | 231 | 258 | |
| 33 | 6 | -2 | 21 | |
| 89 | 24 | 72 | 103 | |
| 15 | -55 | -12 | -2 | |
| 0.09 | -0.35 | -0.08 | -0.01 | |
| 60.5% | 60.2% | 59.9% | 61.5% | |
| 9.7% | 1.8% | -0.4% | 5.0% | |
| 4.4% | -15.6% | -3.1% | -0.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,573 | 1,563 | 1,575 | 1,557 |
| Cash | 237 | 235 | 179 | 189 |
| Total debt | 308 | 303 | 312 | 306 |
| Total liabilities | 493 | 516 | 516 | 494 |
| 1,080 | 1,047 | 1,059 | 1,063 | |
| 159 | 159 | 160 | 160 | |
| 2.1% | -1.9% | 0.2% | 1.6% | |
| 1.4% | -5.3% | -1.1% | -0.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 93 | 83 | 80 | 96 | |
| 13 | 15 | 21 | 27 | |
| 80 | 67 | 59 | 70 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | 43 | |
| 30 | 28 | 35 | 33 |
Valuation
- –
- 25.9×
- –
- 0.9×
- 4.2×
- 25.3×
- 18.4×
- 4.0%
- -0.1%
- 0.0%
Profitability
- 61.5%
- 5.0%
- -0.4%
- 25.8%
- 1.3%
- -1.0%
- -1.4%
- -1.0%
- 1.3%
- 10.2%
Growth
- +7.7%
- –
- +19.9%
- –
- +1.7%
Financial health
- 1.1×
- 0.01
- 0.7%
- 0.4×
- 1.88
- 1.88
- 0.28
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 40%of 946
Bottom 39%of 871
Bottom 38%of 867
Top 27%of 986
What analysts expect
- Average price target
- $10.00
- Range
- $10.00 – $10.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | 0.09 | 0.11 | −18.2% |
| Feb 26, 2026 | 0.09 | 0.11 | −18.2% |
| Nov 6, 2025 | 0.14 | 0.11 | +27.3% |
| Aug 6, 2025 | 0.07 | 0.10 | −30.0% |
| May 5, 2025 | 0.14 | 0.13 | +7.7% |
| Feb 26, 2025 | 0.15 | 0.13 | +15.4% |
| Nov 6, 2024 | 0.13 | 0.11 | +18.2% |
| Aug 6, 2024 | 0.07 | 0.11 | −36.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
59No pass
Philip Fisher
37No pass
Peter Lynch
47No pass
Joel Greenblatt
0No pass
Charlie Munger
34No pass
Terry Smith
33No pass
Questions about Certara
Is Certara a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Certara AI analysis
What does Certara do?
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It is in Medical - Healthcare Information Services.
Does Certara pay a dividend?
No. Certara does not pay a dividend at the moment; in 2025 it returned $42.6 million to shareholders by buying back its own shares.
Is Certara stock halal?
Yes. Certara passes our halal screen: its business is permitted and its debt is 17% of its market value, under the 30% limit. How we check
How has Certara stock done over the past year?
Up 37.6% over the past twelve months, to $11.57. It traded between $4.48 and $12.22 and is 5.3% below its high.
Who are Certara's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with Certara's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.